Who is sponsoring NCT04682860?

NCT04682860 is sponsored by Ankara City Hospital Bilkent.

What drugs are being tested in NCT04682860?

Interventions in NCT04682860: Hyoscine N Butylbromide, Placebo.

What condition does NCT04682860 study?

NCT04682860 studies Acute Gastroenteritis, Abdominal Pain.

Is NCT04682860 still recruiting?

NCT04682860 is currently completed. Last updated 4 January 2022.

Last reviewed 2022-01-04 · How we verify

NCT04682860

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Management of Abdominal Pain in Acute Gastroenteritis Patients With Hyoscine Butylbromide

Completed Phase 4 Last updated 4 January 2022

What this trial tests

Phase 4 trial testing Hyoscine N Butylbromide in Acute Gastroenteritis in 50 participants. Completed in 3 January 2022.

Timeline

8 September 2021

Primary endpoint
3 December 2021

3 January 2022

Quick facts

Lead sponsor	Ankara City Hospital Bilkent
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	50
Start date	8 September 2021
Primary completion	3 December 2021
Estimated completion	3 January 2022
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Hyoscine N Butylbromide — full drug profile →
Placebo

Conditions studied

Acute Gastroenteritis — all drugs for Acute Gastroenteritis →
Abdominal Pain — all drugs for Abdominal Pain →

Sponsor

Ankara City Hospital Bilkent

Who can join

Adults 18 to 65, any sex, with Acute Gastroenteritis or Abdominal Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

One of the most common complaints of admission to the emergency room is gastroenteritis. One of the most common complaints in acute gastroenteritis is abdominal pain. The aim of our study is to investigate whether hyoscine butylbromide used within the indication has an effect on abdominal pain due to acute gastroenteritis. The main purpose of our study is to reduce the pain of the patient at 30th and 60th minutes compared to 0th minute.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hyoscine-n-butylbromide in treating abdominal pain caused by gastroenteritis: a double-blind randomized placebo-controlled study.
Yildirim Ç, Pamukçu Günaydin G. · · 2024 · PMID 39473756 · DOI 10.55730/1300-0144.5864

Verify or expand the search:

Other trials of Hyoscine N Butylbromide

Trials testing the same drug.

NCT04785118 — Hyoscine Butyl-bromide Versus Ondansetron for Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia · Phase 4 · completed
NCT03430362 — Effect Of Intravenous Hyoscine -N-Butyl Bromide In Management Of Prolonged Labor In Nulliparous · NA · completed

Other recruiting trials for Acute Gastroenteritis

Currently open trials in the same condition.

NCT06592794 — A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute · Phase 3 · active not recruiting

Other Ankara City Hospital Bilkent trials

Trials by the same sponsor.

NCT07496788 — Investigation of the Role of Internal Jugular Vein Collapsibility Index in Predicting Spinal Anesthesia-Induced Hypotens · not yet recruiting
NCT07536464 — PEEP Strategies and Mechanical Power in Robotic Surgery · NA · not yet recruiting
NCT07534553 — Mechanical Power Ventilation in RALP · NA · not yet recruiting
NCT07501468 — Ventilation Safety in Beach Chair Shoulder Surgery: SafeLM Versus I-gel · NA · not yet recruiting
NCT07502209 — Suprascapular Nerve PRF in Chronic Shoulder Pain · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04682860 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ankara City Hospital Bilkent
Last refreshed: 4 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04682860.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing